PE20180691A1 - Variantes de il-37 - Google Patents

Variantes de il-37

Info

Publication number
PE20180691A1
PE20180691A1 PE2017002734A PE2017002734A PE20180691A1 PE 20180691 A1 PE20180691 A1 PE 20180691A1 PE 2017002734 A PE2017002734 A PE 2017002734A PE 2017002734 A PE2017002734 A PE 2017002734A PE 20180691 A1 PE20180691 A1 PE 20180691A1
Authority
PE
Peru
Prior art keywords
variants
inflammatory
inflammatory polypeptide
polypeptide
interleukin
Prior art date
Application number
PE2017002734A
Other languages
English (en)
Inventor
Marcel Nold
Claudia Nold
Andrew Ellisdon
James Whisstock
Original Assignee
Univ Monash
Hudson Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902262A external-priority patent/AU2015902262A0/en
Application filed by Univ Monash, Hudson Inst Med Res filed Critical Univ Monash
Publication of PE20180691A1 publication Critical patent/PE20180691A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta referido a un polipeptido antinflamatorio que incluyen variantes de interleucina-37 (IL-37), en donde la secuencia de aminoacidos tiene una mutacion o modificacion que reduce la capacidad del polipeptido antiinflamatorio de formar un dimero. Se refiere, ademas, al uso de los polipeptidos, agentes terapeuticos y composiciones en metodos para tratar enfermedades o afecciones inflamatorias
PE2017002734A 2015-06-15 2016-06-15 Variantes de il-37 PE20180691A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015902262A AU2015902262A0 (en) 2015-06-15 IL-37 variants
AU2016900703A AU2016900703A0 (en) 2016-02-26 IL-37 variants (2)

Publications (1)

Publication Number Publication Date
PE20180691A1 true PE20180691A1 (es) 2018-04-23

Family

ID=57544698

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002734A PE20180691A1 (es) 2015-06-15 2016-06-15 Variantes de il-37

Country Status (17)

Country Link
US (2) US11084855B2 (es)
EP (1) EP3307767B1 (es)
JP (2) JP2018522547A (es)
KR (1) KR20180034390A (es)
CN (1) CN107849109A (es)
AU (3) AU2016281189B2 (es)
CA (1) CA2987437C (es)
CL (1) CL2017003201A1 (es)
CO (1) CO2017013404A2 (es)
CR (1) CR20180008A (es)
HK (1) HK1251001A1 (es)
IL (1) IL256253A (es)
MX (1) MX2017016195A (es)
PE (1) PE20180691A1 (es)
PH (1) PH12017550134A1 (es)
RU (1) RU2017144571A (es)
WO (1) WO2016201503A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511118A (ja) * 2016-12-23 2020-04-16 モナッシュ ユニバーシティ Ｉｌ−３７に対する抗体
WO2018175403A1 (en) 2017-03-20 2018-09-27 Bio-Techne Corporation Il-37 fusion protein and methods of making and using same
WO2021123173A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
US20240075144A1 (en) * 2021-01-08 2024-03-07 Emory University Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE69332197T2 (de) 1992-03-13 2003-04-17 Organon Teknika Bv Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
US6680380B1 (en) * 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
WO2000017363A2 (en) * 1998-09-18 2000-03-30 Schering Corporation Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
AU1322700A (en) * 1998-10-27 2000-05-15 Zymogenetics Inc. Interleukin-1 homolog zil1a4
US20030148467A1 (en) * 1998-10-27 2003-08-07 Zymogenetics, Inc. Interleukin-1 homolog zil1a4
US7033783B2 (en) 1998-12-14 2006-04-25 Immunex Corp. Polynucleotide encoding IL-1 zeta polypeptide
DE69940750D1 (de) * 1998-12-14 2009-05-28 Immunex Corp Xrec2 DNS und Polypeptide
EP1233977A1 (en) * 1999-12-01 2002-08-28 SmithKline Beecham Corporation Interleukin-1 homologue, mat il-1h4
US20130225437A1 (en) 2010-08-16 2013-08-29 THE REGENTS OF THE UNIVERSITY OF COLORADO , a body corporation Biomarkers of cancer
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
CN104083755A (zh) * 2013-11-21 2014-10-08 深圳意达凯生物科技有限公司 含白细胞介素37的药物、其制备方法及应用

Also Published As

Publication number Publication date
IL256253A (en) 2018-02-28
CR20180008A (es) 2018-06-12
EP3307767A4 (en) 2018-12-05
US20180162918A1 (en) 2018-06-14
PH12017550134A1 (en) 2018-03-05
JP2018522547A (ja) 2018-08-16
CL2017003201A1 (es) 2018-07-20
CO2017013404A2 (es) 2018-05-21
CA2987437C (en) 2024-04-09
US11084855B2 (en) 2021-08-10
JP7306655B2 (ja) 2023-07-11
JP2020191860A (ja) 2020-12-03
AU2019203989A1 (en) 2019-06-27
RU2017144571A3 (es) 2019-10-17
AU2021201335A1 (en) 2021-03-18
RU2017144571A (ru) 2019-07-15
EP3307767A1 (en) 2018-04-18
WO2016201503A1 (en) 2016-12-22
HK1251001A1 (zh) 2019-01-18
AU2016281189A1 (en) 2017-12-21
US20220073580A1 (en) 2022-03-10
CA2987437A1 (en) 2016-12-22
CN107849109A (zh) 2018-03-27
EP3307767B1 (en) 2022-01-12
MX2017016195A (es) 2018-09-11
KR20180034390A (ko) 2018-04-04
AU2016281189B2 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201691582A1 (ru) Новые фармацевтические препараты
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
UY37456A (es) Inmunoglobulinas y sus usos
CL2016001405A1 (es) A peptide mixture
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
PE20180691A1 (es) Variantes de il-37
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
EA201791937A1 (ru) Противовоспалительные полипептиды